Baricitinib Is Effective in Patients Treated with DMARDs & Methotrexate

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

References

Dougados M. Presentation: SP0034 EULAR points to consider for reporting, detecting and screening risk factors of selected comorbidities in chronic inflammatory rheumatic diseases in clinical practice. Ann Rheum Dis. 2015;74(suppl 2):9. doi:10.1136/annrheumdis-2015-eular.6756
Kavanaugh AF, van Vollenhoven RF, Muram D, et al. Previous use of conventional disease-modifying anti-rheumatic drugs and response to baricitinib [abstract 1585]. Arthritis Rheumatol. 2016;68(suppl 10).
Fleischmann RM, Huizinga TWJ, Kavanaugh AF, et al. Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. RMD Open. 2016 Jul 26;2(2):e000262. doi: 10.1136/rmdopen-2016-000262. eCollection 2016.

Highlights from the 2017 EULAR Congress MADRID—Tofacitinib (a JAK inhibitor) used with methotrexate (MTX) is not inferior to adalimumab (a TNF inhibitor) plus MTX in rheumatoid arthritis (RA) patients who’ve had an inadequate response to MTX alone, according to results of a Phase 3B/4 trial presented in a session at the Annual European Congress of…

MADRID—Tofacitinib (a JAK inhibitor) used with methotrexate (MTX) is not inferior to adalimumab (a TNF inhibitor) in rheumatoid arthritis (RA) patients who’ve had an inadequate response to MTX alone, according to results of a Phase 3B/4 trial presented in a session at the Annual European Congress of Rheumatology (EULAR). The findings came in a one-year…

In a recent study, baricitinib proved more effective than adalimumab in treating adults with RA through 52 weeks…

Brodalumab Approved for Plaque Psoriasis The U.S. Food and Drug Administration has approved brodalumab, a monoclonal antibody that targets interleukin 17 (IL‑17).1,2 Brodalumab (Siliq) was approved for treating moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and have failed to respond to, or have lost response to, other…

Tofacitinib with Methotrexate Not Inferior to Adalimumab with Methotrexate

Effectiveness of Tofacitinib with Methotrexate, Adalimumab Therapy Evaluated in Patients with RA

Baricitinib May Exhibit Better Efficacy Than Adalimumab for RA

Brodalumab Approved for Plaque Psoriasis, Plus Baricitinib Effiicacy Studied for RA

Related Articles